Pfizer was among the participants as the Asia-focused cancer and cardiorenal drug developer raised $310m in crossover financing.

Lilly Asia Ventures returned for a round that will fund clinical development of Gracell Biotechnologies' immuno-oncology drug pipeline.

Novo, Bristol Myers-Squibb and Merck Group scored exits as the fibrosis and cancer drug developer priced its shares in the middle of the IPO's range.

Sanofi Ventures and Children's Hospital Colorado have returned to back Q32 Bio, an immune regulation-focused university spinout that has now raised at least $106m to date.

ORI Healthcare Fund II has a target of $400m and pharmaceutical firm Hepalink could potentially provide up to $80m for the vehicle.

4100 Group led an extension to the Stanford-StartX Fund-backed healthcare AI technology provider's latest round, which now stands at $30m.

4100 Group led an extension to the healthcare AI technology provider's latest round and was joined by several existing corporate investors.

The fitness and sleep tracker provider, an alumnus of Harvard Innovation Lab, was valued at $1.2bn in a round that took its total funding past $200m.

Spun out of University of Louisville, Koligo Therapeutics has already launched its first cell therapy product and aims to commercialise a treatment for covid-19.

The fitness and sleep tracker provider was valued at $1.2bn in a round that involved SoftBank Vision Fund coming on board as a new investor.